Jacobs Levy Equity Management
JSPR icon

Jacobs Levy Equity Management’s Jasper Therapeutics JSPR Stock Holding History

Jacobs Levy Equity Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-322,273
Closed -$282K – 1015
2026
Q1 		$282K Buy
322,273
+267,473
+488% +$371K ﹤0.01% 888
2025
Q4 		$100K Buy
+54,800
New +$110K ﹤0.01% 907

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jacobs Levy Equity Management's JSPR Position: Q2 2026 in Review

Jacobs Levy Equity Management sold out of Jasper Therapeutics (JSPR) in Q2 2026, closing a stake of 322,273 shares — an estimated $282K sold.

Jacobs Levy Equity Management first reported a position in JSPR in Q4 2025 and held it in 2 quarters. The position peaked at $282K in Q1 2026. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Jacobs Levy Equity Management reported no remaining Jasper Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 322,273 Jasper Therapeutics shares in Q2 2026, an estimated $282K.
  • Jacobs Levy Equity Management first reported a position in Jasper Therapeutics in Q4 2025 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Jasper Therapeutics position peaked at $282K in Q1 2026.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.